MedPath
HSA Approval

ALMACAVIR (ENTECAVIR) FILM COATED TABLETS 0.5MG

SIN16612P

ALMACAVIR (ENTECAVIR) FILM COATED TABLETS 0.5MG

ALMACAVIR (ENTECAVIR) FILM COATED TABLETS 0.5MG

September 23, 2022

ALMA-A PTE LTD

ALMA-A PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantALMA-A PTE LTD
Licence HolderALMA-A PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

**\[DOSAGE AND ADMINISTRATION\]** Recommended Dosage Compensated Liver Disease The recommended dose of Entecavir for chronic hepatitis B virus infection in nucleoside-treatment-naïve adults and adolescents 16 years of age and older is 0.5 mg once daily, with or without food. The recommended dose of Entecavir in adults and adolescents (≥ 16 years of age) with a history of hepatitis B viremia while receiving lamivudine or known lamivudine resistance mutations is 1 mg once daily, which must be taken on an empty stomach (at least 2 hours after a meal and 2 hours before the next meal). Decompensated Liver Disease The recommended dose of Entecavir for chronic hepatitis B virus infection in adults with decompensated liver disease is 1 mg once daily, which must be taken on an empty stomach (at least 2 hours after a meal and 2 hours before the next meal). Renal Impairment In subjects with renal impairment, the apparent oral clearance of Entecavir decreased as creatinine clearance decreased. Dosage adjustment is recommended for patients with creatinine clearance less than 50 mL/min, including patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD), as shown in Table 1. The once-daily dosing regimens are preferred. ![Almacavir Dosage Table 1](https://cdn.medpath.com/drug/dosage/20240520/14b6aa1ff0b11532d039b0e35665d320.png) Hepatic Impairment No dosage adjustment is necessary for patients with hepatic impairment. Duration of Therapy The optimal duration of treatment with Entecavir for patients with chronic hepatitis B virus infection and the relationship between treatment and long-term outcomes such as cirrhosis and hepatocellular carcinoma are unknown.

ORAL

Medical Information

**\[INDICATIONS AND USAGE\]** Almacavir® is indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. The following points should be considered when initiating therapy with Almacavir®: This indication is based on histologic, virologic, biochemical, and serologic responses in nucleoside-treatment-naïve and lamivudine-resistant adult subjects with HBeAg-positive or HBeAg-negative chronic HBV infection with compensated liver disease. - Virologic, biochemical, serologic, and safety data are available from a controlled study in adult subjects with chronic HBV infection and decompensated liver disease. Virologic, biochemical, serologic, and safety data are available for a limited number of adult subjects with HIV/HBV co-infection who have received prior lamivudine therapy.

**\[CONTRAINDICATIONS\]** Entecavir is contraindicated in patients with previously demonstrated hypersensitivity to entecavir or any component of the product.

J05AF10

entecavir

Manufacturer Information

alma-a pte ltd

GENUONE Sciences Inc.

Active Ingredients

Entecavir monohydrate eqv entecavir

0.5mg

Entecavir

Documents

Package Inserts

Almacavir Tablet PI.pdf

Approved: September 23, 2022

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ALMACAVIR (ENTECAVIR) FILM COATED TABLETS 0.5MG - HSA Approval | MedPath